Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
The product will be launched in Q1FY26
The company expects to launch this product through its marketing partner in the near future
Subscribe To Our Newsletter & Stay Updated